Menu

Explaining Elephants’ Cancer Resistance

Two studies reveal that the giant mammals have dozens of extra copies of a cancer-preventing gene.

Oct 13, 2015
Jef Akst

WIKIMEDIA, CHRISTOPHER MICHELWith about 100 times as many cells as a human, a 4,800-kilogram African elephant should, in theory, be more prone to accruing mutations that cause one of those cells to grow out of control. But elephants and other large mammals have surprisingly low rates of cancer, despite living for decades. As Joshua Schiffman, a pediatric oncologist at the University of Utah’s Huntsman Cancer Institute in Salt Lake City, and his colleagues found in a paper published last week (October 8) in JAMA, fewer than 5 percent of captive elephants worldwide die from cancer.

“Long-lived animals with lots of cells should all be dropping dead of cancer,” Schiffman told Science. “But they don’t or they’d go extinct.”

To understand why elephants are apparently cancer resistant, Schiffman and his colleagues scoured the genome of an African elephant and found 40 copies of the p53 gene, known to be important in cancer prevention. The Asian elephant genome contains between 30 and 40 copies of p53. Humans harbor only two copies of the gene. But elephant cells were no better at repairing DNA damage than human cells, in vitro experiments revealed. Instead, the researchers suggested that p53 helps elephants kill off precancerous cells before they become problematic.

Another study published last week (October 6) on the preprint server BioRxiv also found dozens of copies of p53 in the elephant genome, as well as in two extinct species of mammoth. Coauthor Vincent Lynch of the University of Chicago speculated that p53 duplicated as elephant ancestors began to grow in size, but noted that this is likely not the only mechanism to explain the lineage’s cancer resistance.

Cancer biologist Mel Greaves of the Institute for Cancer Research in London agreed. “What would happen if elephants smoked and had a bad diet,” he told Nature. “Would they really be protected from cancer? I doubt it.”

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas Launches Product Portfolio to Mitigate Biotin Interference and Improve Diagnostic Assay Accuracy
Veravas, Inc., an emerging diagnostic company, launched a portfolio of products that can improve the accuracy of current diagnostic test results by helping laboratory professionals detect and manage biotin interference in patient samples with VeraTest Biotin and VeraPrep Biotin.
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
New Data on Circulating Tumor DNA as a Biomarker for Detecting Cancer Progression Presented at 2019 ASCO Annual Meeting
Scientists presented more than 30 abstracts featuring Bio-Rad’s Droplet Digital PCR (ddPCR) technology at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 31–June 4.
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
BellBrook Labs Receives NIH Grant for the Discovery of cGAS Inhibitors to Treat Autoimmune Diseases
The National Institute Of Allergy And Infectious Disease recently awarded BellBrook Labs a $300,000 Small Business Innovative Research (SBIR) grant to develop novel inhibitors for the target cyclic GAMP Synthase (cGAS). The grant will be used to accelerate the discovery of new treatments for autoimmune diseases by targeting the cGAS-STING pathway.